Bio Bridge Science Inc - Amended Current report filing (8-K/A)
12 Agosto 2008 - 1:37PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K/A
CURRENT
REPORT
Pursuant
to Section 13 OR 15(d) of the Securities Exchange Act of
1934
Date
of Report (Date of earliest event reported):
July
31, 2008
|
|
BIO-BRIDGE
SCIENCE, INC.
|
(Exact
name of registrant as specified in its
charter)
|
Delaware
|
|
20-1802936
|
(State
or other jurisdiction of incorporation)
|
(Commission
File Number)
|
(IRS
Employer Identification No.)
|
1211
West 22nd Street, Suite 615, Oak Brook, Illinois
|
60523
|
(Address
of principal executive offices)
|
(Zip
Code)
|
Registrant’s
telephone number, including area code:
630-928-0869
|
Check
the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General Instruction A.2. below):
o
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
o
Soliciting
material pursuant to
Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o
Pre-commencement
communications
pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
o
Pre-commencement
communications
pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
This
Form 8-K and other reports filed by the Registrant from time to time with the
Securities and Exchange Commission (collectively the “Filings”) contain forward
looking statements and information that are based upon beliefs of, and
information currently available to, the Registrant’s management as well as
estimates and assumptions made by the Registrant’s management. When used in the
Filings the words “anticipate”, “believe”, “estimate”, “expect”, “future”,
“intend”, “plan” or the negative of these terms and similar expressions as they
relate to the Registrant or the Registrant’s management identify forward looking
statements. Such statements reflect the current view of the Registrant with
respect to future events and are subject to risks, uncertainties, assumptions
and other factors relating to the Registrant’s industry, operations and results
of operations and any businesses that may be acquired by the Registrant. Should
one or more of these risks or uncertainties materialize, or should the
underlying assumptions prove incorrect, actual results may differ significantly
from those anticipated, believed, estimated, expected, intended or
planned.
ITEM
2.01 COMPLETION OF ACQUISITION OR DISPOSITION OF ASSETS.
As
used
in this report, "we", "us", "our" or "BGES" refer to Bio-Bridge Science, Inc.,
a
Delaware corporation and its subsidiaries.
As
previously reported under Item 2.01 of the Current Report on Form 8-K filed
by
us with the Securities and Exchange Commission on July 31,2008, Bio-Bridge
Science (HK) Co., Ltd., a wholly-owned subsidiary of Bio-Bridge Science, Inc.
entered into an equity sale and purchase agreement with Huhhot Xinheng Baide
Biotechnology Co. Ltd., (the “ Seller” or “Xinheng Baide”), a serum
manufacturing and distribution company organized under the laws of the People's
Republic of China, pursuant to which we agreed to purchase newly issued shares
of Seller. The acquisition was consummated as of July 31, 2008 pursuant to
the
terms of the equity sale and purchase agreement. The description of the
acquisition included in the July 31 is incorporated by reference herein.
This
Current Report on Form 8-K/A provides the historical financial statements of
the
business acquired under Item 9.01(a) and the pro forma financial information
under Item 9.01(b), which financial statements and information were not included
in the July 31 Form 8-K.
ITEM
9.01 FINANCIAL STATEMENTS AND EXHIBITS.
(a)
FINANCIAL STATEMENTS OF BUSINESS ACQUIRED. Huhhot Xinheng Baide Biotechnology
Co.Ltd. audited Financial Statements as of and for the years ended December
31,
2007 and 2006 and unaudited condensed financial statements as of March 31,
2008
and for the three months ended March 31, 2008 and 2007 are filed
as
Exhibit 99.1 to this amendment and incorporated herein by
reference.
(b)
PRO
FORMA FINANCIAL INFORMATION. The pro forma financial information with respect
to
the transaction described in Item 2.01 is filed as Exhibit 99.2 to this
amendment and incorporated herein by reference.
Exhibit Number
|
|
Description
|
|
|
|
99.1
|
|
Financial
Statements of business acquired
|
|
|
|
99.2
|
|
Unaudited
pro forma financial information
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant
has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
|
|
|
|
BIO-BRIDGE
SCIENCE, INC.
|
|
|
|
Date:
August
12, 2008
|
By:
|
/s/ Liang
Qiao, MD.
|
|
Name
|
Liang Qiao, MD.
|
|
Title:
|
Chief
Executive Officer
|
Grafico Azioni Bio Bridge Science (CE) (USOTC:BGES)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Bio Bridge Science (CE) (USOTC:BGES)
Storico
Da Lug 2023 a Lug 2024